Search This Blog

Wednesday, May 20, 2026

Immunovant reaffirms $902M cash position to fund operations through potential Graves’ disease launch

 

Immunovant posts fiscal Q4 2026 loss with non-GAAP EPS -$0.73, revenue $0, misses EPS but beats revenue estimates

  • Company reaffirmed $902M cash position, expected to fund operations through potential Graves’ disease launch.
Posted by at

No comments:

Post a Comment

Note: Only a member of this blog may post a comment.

Subscribe to: Post Comments (Atom)